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Abstract: The botulinum neurotoxins (BoNT, serotypes A-G) are some of the most toxic 
proteins known and are the causative agents of botulism. Following exposure, the 
neurotoxin binds and enters peripheral cholinergic nerve endings and specifically and 
selectively cleaves one or more SNARE proteins to produce flaccid paralysis. This review 
centers on the kinetics of the Zn-dependent proteolytic activities of these neurotoxins, and 
briefly describes inhibitors, activators and factors underlying persistence of toxin action. 
Some of the structural, enzymatic and inhibitor data that are discussed here are available at 
the botulinum neurotoxin resource, BotDB (http://botdb.abcc.ncifcrf.gov). 
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1. Introduction  
This review focuses on the enzymatic function, thermodynamic properties and susceptibility to 
inhibitors and activators of the botulinum neurotoxins (BoNTs), the causative agents of botulism. 
These neurotoxins are metalloproteases (E.C. 3.4.24.69) that belong to the gluzincin clan [1] and the 
MA(E) clan/M27 family as classified by the MEROPS database [2]. These multi-domain bacterial 
proteins are produced by Clostridium botulinum and related species (C. argentinense, baratii, 
butyricum) and are categorized into seven immunologically distinct serotypes (A-G). In cases of food 
poisoning, the ingested toxin migrates from the gastrointestinal tract and eventually reaches its primary 
targets, the peripheral cholinergic nerve terminals to cause flaccid paralysis. The botulinum 
neurotoxins (BoNTs) are released from the bacteria in complex with various non-toxic proteins that 
serve to protect the neurotoxin from the degrading proteolytic and low pH environments found in the 
gastrointestinal tract [3].  
An eighth homologous neurotoxin produced by C. tetani (tetanus neurotoxin, TeNT) causes spastic 
paralysis (tetanus) and is unaccompanied by accessory proteins [3]. Interestingly, TeNT and BoNT/B 
share the same molecular target (VAMP) and specifically cleave at the same peptide bond (see   
Section 2). In contrast to the BoNTs, tetanus neurotoxin (TeNT) enters these same cholinergic termini, 
is retrogradely transported within motor nerve axons to the spinal cord and is translocated into 
inhibitory neurons where it produces disinhibition leading to spastic paralysis [4,5]. Thus, the same 
general mechanism of proteolytic action produces two distinct symptoms that are dependent on their 
cellular location [6]. Moreover, at concentrations higher than those encountered in vivo, TeNT 
produces flaccid paralysis in isolated nerve-muscle preparations [5].  
Clinical signs and symptoms of botulism consist of an assortment of abnormalities including those 
related to the neuromuscular junction and the autonomic nervous systems: dilated pupils, descending 
symmetric flaccid paralysis, dizziness, blurred vision, dry mouth, sore throat, constipation, nausea, 
vomiting, abdominal cramps, diarrhea, and paresthesia [7].  
From a basic research perspective, these homologous neurotoxins have been exploited as 
pharmacologic tools for elucidating the role of the conserved SNAREs that regulate neurally evoked, 
Ca
2+-dependent release of neurotransmitter from synaptic vesicles. In stark contrast to their roles as 
poisons, the type A and B toxins have been commercially developed as therapeutic agents for a variety 
of focal dystonias, autonomic dysfunctions, and cosmetic treatments [8–10].  
These bacterial neurotoxins (molecular weight ~150 kDa) have four domains that comprise their 
three-dimensional (3D) structures (Figure 1) [11–15]. BoNT/A was the first holotoxin serotype to be 
resolved crystallographically [17] (PDB ID: 3BTA). The zinc-dependent proteolytic activities of the 
light chains (LCs) of BoNT serotypes A, B, and E were first reported in 1992 by Schiavo et al. [18] 
and the metalloprotease activity for the structurally homologous TeNT light chain was published 
during the same year [19]. When expressed, the neurotoxin molecule (progenitor toxin) is a single 
polypeptide chain. An initial post-translational modification is ‘nicking’, in which several amino acid 
residues are removed about a third of the way downstream from the N-terminus. This modification 
results in two chains that are connected by a disulfide bridge.  
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Figure 1. Representation of the four structural domains of the BoNT/B holotoxin (PDB ID 
1EPW)  [16]. The “Structures” section of the BotDB presently contains 90 3D protein 
structures found in the Protein Data Bank (PDB) [5]. From left to right, the order of these 
domains is: HCC, (red) HCN, (yellow-orange) HN (green), LC (blue).  
 
 
The N-terminal domain of BoNT, the LC (~50 kDa), is displayed on the right-hand side in Figure 1 
and functions as a zinc-dependent protease. The SCOP database [20] classifies these LCs as a mixture 
comprised of -helices + -strands, remarkably similar to the metalloprotease domain of anthrax lethal 
factor [21]. The LC is widely accepted to be the toxic moiety of the BoNTs. Although much is known 
about the role of the BoNT domains, there is no explanation available as to the mechanism involved in 
the separation of the heavy and light chains that are tightly held together by ionic interactions [22]. 
Under laboratory conditions this separation of chains typically occurs in a high pH, reducing, high 
ionic strength environment, i.e., pH 8.4 buffer containing 0.01 M dithiothreitol, 2 M urea, and   
0.2 M NaCl [23]. Further studies are required to characterize the mechanism of this separation as it is 
assumed to occur in living cells.  
Surrounding the LC is a relatively unstructured sequence of ~100 amino acids that is part of the  
N-terminal sequence of the heavy chain (HC). This “belt”, at least in BoNT/A, seems to sterically 
protect the binding region for the substrate SNAP-25. It has been suggested that the type A belt acts as 
a chaperone for the translocation of the LC [24]. The belt has also been conjectured to act as a Toxins 2010, 2                 
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surrogate or a pseudo-substrate [24]. The function of the belt in BoNT/B is less certain because 
available 3D structures show that it is shifted away from the substrate binding region [16].  
The heavy chain (HC, ~100 kDa) has three structurally dissimilar domains. The so-called   
C-fragment is composed of two all-domains (HCC and HCN, ~50 kDa; far left-hand side of Figure 1, 
red and yellow-orange). Together, the HC domains recognize and bind to nerve terminals in a serotype 
specific manner using proteins, gangliosides or other macromolecules as receptors [25]. The other 
domain (HN, ~50 kDa, green) is mainly helical (middle portion of Figure 1) and assists in the 
receptor-mediated internalization and translocation of the toxic moiety [26]. This multistep mechanism 
of neurotoxin action was first enunciated by Simpson (1980) [27] and has been kinetically modeled 
[27,28]. It is worth emphasizing that these neurotoxin molecules are not merely proteases. Rather, they 
are naturally occurring nano-scale machines [11] that bind and enter into cholinergic nerve endings to 
deliver their enzymatic cargos. The BoNTs are highly selective for their substrates, which regulate 
vesicle-mediated neurotransmission.  
2. Proteolytic Activity  
The clostridial neurotoxins are noted for their substrate selectivity and cleavage site specificity. 
Only BoNT/C1 has been shown to attack two different SNARE proteins, syntaxin1 and SNAP-25 
(Table 3; [6,29–32]). Specificity [33] describes the level of restriction of the cleavage sites at peptide 
backbone locations in a each substrate. Only TeNT and BoNT/B attack the same substrate (VAMP) at 
the same peptide bond (Q76-F77, human sequence, UniProtKB accession P63027 [34]).  
The first deduced amino acid sequence of a clostridial neurotoxin was determined for TeNT [35]. 
From this sequence, TeNT was predicted to be a Zn-dependent protease [36]. This frequently 
overlooked bioinformatic forecast was based solely on the zincin sequence pattern (HExxH) that is 
found to be associated with the active-site of the prototypical metalloprotease thermolysin. This 
prediction was experimentally verified and localized to the LC [18,37,38]. As expected, this protease 
activity can be blocked by chelators [29,39].  
The clostridial neurotoxins belong to the gluzincin subgroup of metalloproteases that has the 
HExxH…E pattern [1,40]. For the BoNT/A sequence (strain Hall / ATCC 3502 / NCTC 13319; 
UniProtKB accession BXA1_CLOBH), the invariant histidine and glutamate residues (H223, H227, 
E262) form non-covalent bonds with the zinc ion and the glutamate (E224) is the active site residue. A 
more detailed version summarizing a 10-residue consensus pattern of the Zn-binding region is 
described in the Prosite database [20] for neutral zinc metallopeptidases.  
The variability of LC sequence identity percentages ranges from 31–59% when pair-wise 
alignments are performed with the seven BoNT serotypes and TeNT [41] (Table 1). The substrate 
locations cleaved by the seven BoNT serotypes are summarized in Table 2 [6]. Representations of the 
3D structures of the BoNT holotoxin, LC, C-fragment (HCC) and a variety of mutants along with 
references and other material are located at the BotDB resource (see Table 3). 
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Table 1. Pairwise sequence similarities and identities of the BoNT/A-G and TeNT light 
chain. % similarity is shown above the diagonal and % identity below the diagonal. Table 
modified from Lebeda and Olson [41]. 
% similarities 
 /A  /B  /C1  /D  /E  /F  /G  TeNT 
/A  -  52 52 54 54 53 53 52 
/B  31 -  54 53 58 58 75 68 
/C1  33 33 -  61 54 56 53 55 
/D  34 33 56 -  54 55 54 54 
/E  34 37 35 36 -  72 58 62 
/F  34 38 35 36 58 -  59 62 
/G  35 59 35 36 38 40 -  66 
TeNT  31 50 34 34 44 44 49 - 
% identities 
Table 2. A summary of the BoNT serotypes, their target SNARE proteins, their 
intracellular compartments and the cleavage site locations. This table is available at the 
BotDB website. 
 
It should be noted that in rats, VAMP1 unlike VAMP2, is not cleaved by BoNT/B because it has 
VF instead of QF that is located at this cleavage site in the corresponding mouse or human proteins. 
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Table 3. A partial list of 3D structures, which are hyperlinked to other features in the BotDB 
a. 
 
a Abbreviations in the right most column are linked to various sites: J, Jmol graphics program; P, PDB 
website; Pf, PDB file; D, DSSP Summary; bXm, literature reference from botXminer; Pm, PubMed; Inh, 
inhibitor. 
There is also evidence for the need of relatively long minimal substrates to support cleavage. For 
example, a 62-mer VAMP fragment for TeNT [42], and a 17-mer SNAP-25 fragment for BoNT/A [43] 
have been documented.  The need of relatively long minimal substrates is consistent with the 
computational results in which the binding free energy in the model became more favorable as the 
substrate (a VAMP fragment) bound in a zipper-like manner to form a complex with the LC of 
BoNT/B [44]. 
 
One conclusion from these observations is that there is a requirement for the substrate to bind at 
sites that are distal to the active site. From analysis of multiple sequence alignments, it was noted that 
substrate selectivity could be provided “by the critical positioning of the substrate by the non-perfectly 
conserved residues … plus the residues flanking the active-site region“ [45]. From X-ray 
crystallographic studies by Brunger’s group, the discontinuous binding locations for SNAP-25 are 
distal to the catalytic site. The term exosites defined these locations on the BoNT/A-LC [46]   
(PDB ID: 1XTG; Table 3). Substrate specificity was described in terms of an array of exosites. An 
abundance of binding sites is in accord with the enzyme-substrate interface area of 4,840 Å
2 for 
BoNT/A that is about four times larger than the typical protein-protein interface [47]. 
The structures of the active sites of three neurotoxins (A, B and E) were considered to be virtually 
identical. From this analysis it was concluded that substrate recognition does not occur at the catalytic 
machinery [46]. Furthermore, the data showed that substrate binding induced structural changes that 
probably influenced catalytic activity and that the rational design of specific inhibitors of BoNT/A 
could benefit from a knowledge of the exosite structures that recognize the substrate [46]. Toxins 2010, 2                 
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3. Enzyme Kinetics 
Cell-free assays were initially developed in which the toxin was combined with the appropriate 
substrate and kinetics of substrate cleavage could be monitored and analyzed [30,41,46–49]. Initially, 
samples of holotoxin that were isolated and purified from the organism were used. When recombinant 
techniques were able to express the LC in E. coli or yeast, this toxin fragment replaced the holotoxins 
in these assays. 
Experimental conditions are critical determinants for the outcomes–a wide range of Km and kcat 
values have been reported under different cell-free conditions (Figure 2) [48–50].  
Figure 2. Values of Km and kcat obtained from cell-free assays depend on the forms of the 
toxic moiety and the substrate molecule used. The LC of BoNT/A (LC-A) and full length 
SNAP-25 (residues 1–206) are associated with values of Km (closed symbols) that are less 
than those associated with the LC-A and a 17-mer of SNAP-25 (residues 146–206; open 
symbols). Larger values for kcat tended to be associated with a 17-mer of SNAP-25 and the 
holotoxin (open triangles). Open circles: LC-A used with 17-mer SNAP-25 fragment; 
closed circles: LC-A used with full-length SNAP-25 (1–206) containing His-6 tag. Closed 
diamond: data associated with the largest kcat/Km ratio in this data set (see text). Dashed 
vertical line: arbitrarily positioned below Km = 100 M to visually separate high and low 
values of Km. Data collected from [48–50] and references therein. 
 
In general, experiments with LC-A and SNAP-25 fragments >61 residues or full length substrates 
produce a range of kcat/Km values (10
4 to 10
6 s
-1M
-1) that is larger compared to the range determined 
from experiments with LC-A and the 17-mer SNAP-25 fragment (10
2 to 10
3 s
-1M
-1). Experiments 
using reduced holotoxin produced a similar quantitative trend, in which the full length substrate was 
associated with larger values for kcat/Km than those observed using the 17-mer fragment.  
As the ratio kcat/Km increases, the enzymatic performance usually increases. The term “performance 
constant” has been suggested for this ratio and is considered to be a more accurate descriptor than the 
“specificity constant” [51]. The largest ratio in the data set shown in Figure 1 (filled diamond) is  
60 s
-1/16.2 M or 3.7 × 10
6 s
-1M
-1 [52] using the LC-A (1-425) and a 61-mer SNAP-25 fragment. This Toxins 2010, 2                 
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ratio is 2–3 orders of magnitude below the diffusion limit [53], suggesting that only in a fraction of 
substrate-enzyme collisions are productive and, therefore, the cleavage reaction appears to be the 
limiting step.  
This toxin-substrate combination may represent an optimal condition for selecting a standard for 
testing active-site inhibitors in cell-free assays. Taking into consideration that this ratio has not been 
measured within the intracellular milieu of presynaptic termini (Section 6), it is currently premature to 
define standards based on the kinetic values obtained in cell-free systems. Rather a set of different  
cell-free conditions may be necessary to evaluate the effectiveness of candidate inhibitors (Section 4). 
To support the idea that the catalytic step is indeed rate limiting, one can calculate the value of the 
dissociation reaction rate of the toxin-substrate complex and compare it to the value of kcat. Relatively 
few studies have determined the dissociation constant (Kd) for the SNAP-25 BoNT/A interaction   
[50,54]. To achieve this experimentally, mutants were developed to produce a non-cleavable substrate 
and a value of Kd = 2.33 × 10
-7 M was determined [50]. This value along with the Km and kcat values of 
the toxin- cleavable substrate reaction, forward (k1) and backward (k-1) rates for the dissociation 
reaction can be calculated. Assuming that the following reaction occurs 
k1       kcat 
E + S ⇌ ES  E + P 
    k-1 
and that Michaelis-Menten kinetics are obeyed to generate the product (P), the equations for Km  
1 1 / ) ( k k k K cat m                 (1) 
and Kd 
1 1/k k Kd            (2) 
can be solved to yield the on rate 
) /( 1 d m cat K K k k           (3) 
and the off rate 
d K k k * 1 1               (4) 
of the substrate (S) with respect to the toxin (E). In the experiments using the wild type LC-A and the 
recombinant SNAP-25 His6-tagged substrate, where Km = 9.8 × 10
-6 M, kcat=1.71 × 10
1 s
-1, and   
Kd = 2.33 × 10
-7 M [50], the calculated values of k1 and k-1 are 7.7 × 10
12 s
-1M
-1 and 1.8 × 10
6 s
-1, 
respectively. Using equations 3 and 4, the value of kcat is about 10
5 times slower that k-1. Using a LC-A 
concentration of 100 nM results in a forward rate, k1[E] = 7.7 × 10
5 s
-1, which is more than 10
4-times 
faster than kcat. Thus, these calculations support the idea that product formation is the rate-limiting step 
in reaction 1. 
4. Inhibitors  
In the quest for inhibitors that antagonize the toxic effects produced by the clostridial neurotoxins, 
well-studied inhibitors of other enzymes, such as thermolysin and angiotensin converting enzyme 
(ACE), were initially tested. Depending on experimental conditions, the blockade of TeNT activity did 
not occur with high concentrations of phosphoramidon, thiorphan or trans-epoxysuccinic acid (E64), 
which inhibits thiol proteases [55]. On the other hand, phosphoramidon, a thermolysin inhibitor, was Toxins 2010, 2                 
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effective against the TeNT LC [37] or was a weak inhibitor of VAMP cleavage by BoNT/B [56]. 
Phosphoramidon moderately prolonged the half- times-to-block produced by BoNT/A or B at the NMJ 
[57]. Captopril, a potent ACE inhibitor, at a relatively high (1.5 mM) concentration only produced a 
short delay before complete BoNT-induced paralysis in NMJ preparations [57,58].  
Because of the neurobiology associated with these neurotoxins, blocking their effects may involve 
more than antagonizing their catalytic activity and, consequently, a variety of additional approaches 
have been attempted. The toxin domains that take part in the multi-step intoxication reactions for 
BoNT binding, internalization, translocation and toxicity have been targets of a variety of candidate 
inhibitors. For example, several naturally occurring lectins containing sialic acid were effective   
(Ki ~ 100 nM) in preventing BoNT/ A, B, C1, D, E, F and TeNT from binding to presynaptic   
terminals [59].  
Internalization and translocation of the toxic moiety requires acidic vesicular compartments and 
metabolic energy. Agents that prevent pH drops that accompany vesicle-mediated endocytosis have 
been examined. Proton ionophores, nigericin and monensin, which are thought to antagonize the 
translocation of the LC, produced delays in the production of toxicity in NMJ preparations [58]. Other 
blockers of vesicular acidification, chloroquine, aminoquinolines [60] and selected quinolines [61] 
have also been tested. The onset of paralysis in NMJ experiments caused by BoNT/A, B, and C1 were 
blocked in a concentration-dependent manner with millimolar amounts of ammonium chloride and 
methylamine hydrochloride. Internalization was delayed and the toxins were susceptible to 
extracellular antibodies [62]. Uncouplers of oxidative phosphorylation CCCP, FCCP [58] and 
inhibitors of vesicular H
+ ATPase [63] have also been examined. Some of these compounds were toxic 
and, at best, those that were not toxic had low safety margins that prevented them from being 
considered as therapeutic candidates. In addition, some candidate compounds may transiently 
antagonize the effects of some serotypes (e.g., BoNT/A). Selected aminopyridines act indirectly by 
blocking K
+ channels which prolongs action potential durations and increases Ca
2+ influx into nerve 
terminals thereby transiently overcoming the effects of BoNT/A [64–66]. 
With respect to the development of candidate inhibitor compounds, the toxic reaction step involving 
the proteolysis of one of the SNARE proteins has been the major focus of attention over the past  
10 years. A variety of conventional and novel approaches have been used to develop active-site 
inhibitors and only a few examples will be mentioned here. Extensive in vivo testing has been delayed 
in favor of screening candidate inhibitors using isolated, mouse phrenic nerve-hemidiaphragm 
preparations [67]. More recently, studies have sought to understand the properties of the reactants and 
the minimal requirements for proteolysis in cell-free preparations. As mentioned in Section 2, 
determinations have been made of which substrate fragments can support cleavage by a neurotoxin 
[32,43,68–71]. Some of these studies evolved into searches for peptide inhibitors of this reaction 
including synthetic peptides with proline-rich motifs [72]. Investigations of peptide inhibitors have 
inspired the development of substrate-based peptidomimetics as novel active-site inhibitors [73].  
Low molecular weight organic compounds have been synthesized and screened for inhibitory 
activity. A crystallographic study of BoNT/B in complex with bis(5-amidino-2-benzimidazolyl) 
methane revealed that this compound had rearranged the active site, and removed the zinc ion that, 
presumably, caused the loss of proteolytic activity [74]. Vast quantities of products emerging from 
combinatorial chemical techniques [75] have been subjected to high throughput screening   Toxins 2010, 2                 
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systems [76]. In contrast, the pharmacophore concept and structure-activity relationships (SAR) for 
drug discovery have exploited computational chemistry techniques [77]. Computer aided designs have 
enabled the refinement of a lead compound having an IC50 value of 100 M to one having a Ki value 
of 760 nM [47]. A recent inhibitor designed on SAR principles has been co-crystallized with   
BoNT/A-LC (PDB ID: 3DSE) and has a Ki value of 41 nM [78]. In this case, tight-binding inhibitor 
kinetics may be more appropriate for analysis than traditional competitive inhibitor models [79].  
Some of these procedures have led to the development of the first irreversible inhibitor based on a 
benzylidene cyclopentenedione structure whose mechanism involves covalent modification of the 
active site [80]. Most recently, the identification of exosites [73] on the LC-A (Section 2) has led to the 
development of non-competitive blockers of substrate binding at these sites as exemplified by the 
natural product d-chicoric acid (I1) from Echinacea [81]. It will be important to determine how toxic 
these compounds are in cultured cells and in animal models. From a toxicity perspective, it will be 
important to understand the findings of Janda’s group [82], in which the two most efficacious 
compounds  in vivo showed less activity in cellular assays. Indeed, one of these compounds was 
cytotoxic at concentrations three orders of magnitude below its effective dose in vivo. 
Within the BotDB resource, the BotDBI section has information on more than 60 inhibitor 
candidates including peptides, synthetic and natural compounds, and monoclonal antibodies, along 
with references. Searches for candidate inhibitors can be done by author name, value of IC50, inhibitor 
site, inhibitor type, value of Ki, inhibitor name PubMedID BoNT serotype, and inhibitor structure. An 
example of a list of synthetic compounds in the BotDBI section is shown in Figure 3.  
Figure 3. Example list of compounds in the BotDBI that have been evaluated as blockers 
of BoNT/A action.  
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In another part of the BotDB resource is an on-line, user friendly tool that converts IC50 to Ki values 
depending on whether the inhibitory mechanism is competitive, uncompetitive, or noncompetitive 
(Figure 4) [79]. The upper portion of this output lists the parameter values (in M units) that need to be 
entered by the end user, i.e., enzyme (toxin) concentration, substrate concentration, Km and IC50. The 
middle panels display the results from the Ki calculations assuming that three different mechanisms 
follow either the classic (Michaelis-Menten) scheme or are associated with a tightly bound inhibitor. 
The bottom panel has color-coded histograms for classic (red bars) and for tightly bound (blue bar) 
inhibitors from six different calculations for the Ki values. This display allows the user to visualize and 
readily compare the results.  
Figure 4. Output of the IC50-to-Ki converter tool at the BotDB website that shows the 
different possible results based on whether the inhibitor mechanism is competitive, 
uncompetitive or noncompetitive.  
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5. Activators  
Schmidt and Bostian [83] described the stimulating effects of bovine serum albumen (BSA) and 
other serum albumins that were kinetically analyzed by following the BoNT/A-mediated cleavage of 
the 17-mer SNAP-25 fragment by BoNT/A. Addition of 1 mg/ml BSA, produced a 10-fold increase in 
the value of kcat and a three-fold decrease in Km leading to an increase of 30-fold for the performance 
constant (kcat/Km, Section 3). This enhancing effect of BSA has been noted with other enzymes [84]. 
Beyond an apparent non-specific stabilizing effect that may underlie the action of BSA, some   
low-molecular weight synthetic ligands having a 2-acylguanidyl-5-phenyl thiophene scaffold have 
been reported to activate the enzymatic effects of BoNT/A under cell-free conditions [85]. In that 
study, the value of Km was reduced by the ligands while the value of kcat was essentially unaffected. 
Importantly, this activation was determined not to be a detergent-like effect. The results were so 
striking that these authors described their compounds as being super-activators.  
One implication of these findings may affect the use of these toxins as pharmaceutical treatments 
for a variety of conditions and disorders. A better therapeutic strategy may be created if these 
activating compounds were part of the toxin formulation. Ideally, less toxin would be needed to 
produce an optimal level of therapeutic benefit, thus reducing the incidence of toxic side effects and 
causing or development of resistance to treatment.  
At higher concentrations, some ligands may exhibit both stimulatory and inhibitory effects. The 
theoretical basis for this dual mechanism for a single ligand have been kinetically analyzed in detail by 
others, e.g., [86,87]. Such a concentration-dependence is predicted to be observed in cell-free systems 
using a wider range of inhibitor and substrate concentrations than have thus far been examined. 
6. Future Research 
The long-lasting effects of botulism are well known [12,14,88] with patients still presenting some of 
the toxic signs and symptoms a year after onset. In one extreme case, the effects due to type A toxin 
poisoning persisted for over five years [89]. It is clinically relevant to understand the underlying 
mechanism of persistence. As mentioned in Section 5, the presence of an additive that prolongs the 
persistence of BoNT-induced effects could be exploited by caregivers to provide longer lasting 
therapeutic effects with a reduced number of injection sessions along with fewer and less severe 
adverse reactions for the patient. 
Two hypotheses have been advanced. The long lasting activity of the type A toxin was 
hypothesized to be based on the longevity of the LC within the nerve terminal [90,91] or to a slower 
turnover of the truncated SNAP-25 generated by BoNT/A-mediated proteolysis. Presently, there is no 
direct evidence for either the BoNT LC or for the SNAP-25 cleavage products to have a long half life. 
Moreover, the proposed long-lived activity of the BoNT/A LC is apparently not due to an 
extraordinary thermostability compared to that of thermolysin. This is because the estimated activation 
energy for unfolding, Ea, is ~ 9 kJ/mol for the reduced form and 22 kJ/mol for the unreduced form of 
BoNT [92]. These values are low in comparison with the Ea for inactivation of the more temperature 
stable thermolysin which is ~149 kJ/mol [93].  Toxins 2010, 2                 
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Dolly and colleagues challenged the view that BoNT/A activity was extraordinarily stable. These 
researchers hypothesized that the protracted time course of the toxic effects was due to the truncated 
SNAP-25 that results from BoNT/A-mediated cleavage of the last nine C-terminal residues [94–96]. 
Evidence was presented in which one of the cleavage fragments formed a long-lasting but incompetent 
SNARE complex with syntaxin and VAMP. Normally the SNARE complex dissociates into the three 
monomers in conjunction with -SNAP [-soluble N-ethylmaleimide-sensitive fusion protein (NSF) 
attachment protein] and NSF [97,98]. 
An issue that may be related to the persistence phenomenon is the differential localization of the 
LCs for BoNT/A and E. A di-leucine motif is present in the LC of BoNT/A, but does not exist in the 
LC of BoNT/E. It is believed that this motif functions as a sorting signal to keep the LC-A associated 
with the cytoplasmic surface of the nerve terminal, while the LC-E is removed from this site and 
presumably metabolized into an inactive form [99]. 
Focusing on the LC stability portion of this hypothesis, mechanisms unique to the intracellular 
environment may lead to persistence of LC-A within nerve terminals that may not occur in cell-free 
systems. For example, persistence of proteolytic activity could be due to post-translational 
modifications (PTMs) of LC-A or as a consequence of interactions of LC-A with molecules that serve 
as molecular chaperones. Like other enzymes, BoNT is regulated through post-translational 
modifications such as the nicking process that creates the LC and HC (Section 1) along with the 
reduction of the interchain disulfide bond that is essential to the activation of BoNT or TeNT [29,38]. 
What is not known to any great extent are other possible covalent modifications in which low 
molecular weight groups are added. The existence of phosphorylation of tyrosines of the type A, B, E 
and TeNT LCs [100], which may enhance its thermal stability while retaining its catalytic properties 
has been reported but is of uncertain functional significance within neurons [101]. Within the 
environment of the nerve terminal, rate constants (Section 3) may be affected by molecular crowding 
or confinement [102]. Protein structural stability and enzymatic efficiency could be enhanced by 
endogenous substances that are usurped by the toxin to act as molecular chaperones. Such concepts 
provide a physical basis for long-lived enzyme activity when considering persistence of BoNT/A and 
perhaps other serotypes. 
Because the persistence hypotheses considered above are not mutually exclusive, both could be 
merged into a single framework to account for long-term paralysis. Future research is required to 
advance our understanding of this intriguing phenomenon and the related problem of developing 
activator additives to improve the BoNT therapeutic effects of the BoNTs. In addition, continued 
improvements are needed in developing inhibitors to ameliorate BoNT toxicity. These would be used 
for treatment of overdose following clinical use, for treatment of accidental intoxication in the human 
and animal populations and most importantly for treatment of casualties after a bioterrorist attack. 
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